Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Ciprofloxacin on PK of Ivacaftor and VX-661
NCT02015507Phase 1Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Jan 2014
- Primary completion
- Feb 2014
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of tezacaftor in cystic fibrosis (CF) (2 cohorts), sponsored by Vertex Pharmaceuticals. Primary endpoints: PK parameters of ivacaftor and metabolites following concomitant dosing with ciprofloxacin relative to ivacaftor administered alone at Day 14 and PK parameters of VX-661 and metabolites when dosed in combination with ivacaftor and concomitant ciprofloxacin relative to VX-661 administered in combination with ivacaftor at Day 20. Started Jan 2014; status: completed.
02
Drugs
tezacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02015507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02015507.